THE DEAL, AT A GLANCE
From the announcementBios Life
What it doesBios Life provides an AI-native predictive cancer surveillance and care platform.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Who is involvedBacked by Redmile Group, Vsquared Ventures, Kindred CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedBios Life raised $25M Seed, announced 2026-08-11From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersBios Life is using a $25M Seed round to build a personalized cancer screening and survivorship care platform for high-risk individuals and cancer survivors.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Bios Life · Financing Record
Explore source-linked visual explanations for Bios Life. Unsupported claims are withheld while source review continues.
Record 10017 · Recorded date: 2026-08-11
Explore company records →